Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGR-2921 in relapsed/refractory AML and MDS
NCT05961839Phase 1Terminated
- Sponsor
- Schrödinger
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SGR-2921 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Schrödinger. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Adverse Events at 26 months and 1 more. Started Sep 2023; status: terminated.
02
Drugs
SGR-2921
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05961839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961839.